nodes	percent_of_prediction	percent_of_DWPC	metapath
Indomethacin—PTGS2—muscle cancer	0.202	1	CbGaD
Indomethacin—ABCC6—Dactinomycin—muscle cancer	0.0942	0.148	CbGbCtD
Indomethacin—ABCC11—Methotrexate—muscle cancer	0.0612	0.0958	CbGbCtD
Indomethacin—ABCC6—Etoposide—muscle cancer	0.0532	0.0833	CbGbCtD
Indomethacin—AKR1C3—Doxorubicin—muscle cancer	0.0482	0.0755	CbGbCtD
Indomethacin—ABCC6—Doxorubicin—muscle cancer	0.0363	0.0568	CbGbCtD
Indomethacin—ABCC3—Vincristine—muscle cancer	0.0279	0.0437	CbGbCtD
Indomethacin—ABCC1—Dactinomycin—muscle cancer	0.0278	0.0435	CbGbCtD
Indomethacin—ABCC3—Etoposide—muscle cancer	0.0255	0.04	CbGbCtD
Indomethacin—UGT1A1—Etoposide—muscle cancer	0.0191	0.0299	CbGbCtD
Indomethacin—ABCC3—Doxorubicin—muscle cancer	0.0174	0.0273	CbGbCtD
Indomethacin—ABCC1—Vincristine—muscle cancer	0.0171	0.0268	CbGbCtD
Indomethacin—ABCC3—Methotrexate—muscle cancer	0.0169	0.0264	CbGbCtD
Indomethacin—ABCC1—Etoposide—muscle cancer	0.0157	0.0246	CbGbCtD
Indomethacin—SLC22A11—Methotrexate—muscle cancer	0.0139	0.0217	CbGbCtD
Indomethacin—SLC22A7—Methotrexate—muscle cancer	0.0132	0.0207	CbGbCtD
Indomethacin—ABCC4—Methotrexate—muscle cancer	0.0129	0.0202	CbGbCtD
Indomethacin—ABCC2—Vincristine—muscle cancer	0.0127	0.0198	CbGbCtD
Indomethacin—ABCC2—Etoposide—muscle cancer	0.0116	0.0182	CbGbCtD
Indomethacin—PTGS2—Etoposide—muscle cancer	0.0115	0.018	CbGbCtD
Indomethacin—ABCC1—Doxorubicin—muscle cancer	0.0107	0.0168	CbGbCtD
Indomethacin—ABCC1—Methotrexate—muscle cancer	0.0104	0.0162	CbGbCtD
Indomethacin—PTGS1—Etoposide—muscle cancer	0.00969	0.0152	CbGbCtD
Indomethacin—SLCO1A2—Methotrexate—muscle cancer	0.00925	0.0145	CbGbCtD
Indomethacin—SLCO1B1—Methotrexate—muscle cancer	0.00873	0.0137	CbGbCtD
Indomethacin—SLC22A8—Methotrexate—muscle cancer	0.00806	0.0126	CbGbCtD
Indomethacin—ABCC2—Doxorubicin—muscle cancer	0.00792	0.0124	CbGbCtD
Indomethacin—ABCC2—Methotrexate—muscle cancer	0.00767	0.012	CbGbCtD
Indomethacin—ABCB1—Dactinomycin—muscle cancer	0.00671	0.0105	CbGbCtD
Indomethacin—SLC22A6—Methotrexate—muscle cancer	0.00561	0.00879	CbGbCtD
Indomethacin—ALB—Methotrexate—muscle cancer	0.00478	0.00748	CbGbCtD
Indomethacin—ABCB1—Vincristine—muscle cancer	0.00413	0.00647	CbGbCtD
Indomethacin—ABCB1—Etoposide—muscle cancer	0.00378	0.00593	CbGbCtD
Indomethacin—CES1—larynx—muscle cancer	0.00333	0.0544	CbGeAlD
Indomethacin—ABCB1—Doxorubicin—muscle cancer	0.00258	0.00404	CbGbCtD
Indomethacin—ABCB1—Methotrexate—muscle cancer	0.0025	0.00392	CbGbCtD
Indomethacin—PPARG—hindlimb—muscle cancer	0.00192	0.0313	CbGeAlD
Indomethacin—PTGR2—embryo—muscle cancer	0.00185	0.0302	CbGeAlD
Indomethacin—ABCC11—embryo—muscle cancer	0.00183	0.0299	CbGeAlD
Indomethacin—PTGDR2—tendon—muscle cancer	0.00165	0.0269	CbGeAlD
Indomethacin—PPARG—appendage—muscle cancer	0.00164	0.0268	CbGeAlD
Indomethacin—PTGR2—renal system—muscle cancer	0.0014	0.0229	CbGeAlD
Indomethacin—PTGR2—cardiac atrium—muscle cancer	0.00125	0.0205	CbGeAlD
Indomethacin—ABCC6—Podofilox—Etoposide—muscle cancer	0.00111	0.344	CbGdCrCtD
Indomethacin—PTGR2—tendon—muscle cancer	0.00109	0.0179	CbGeAlD
Indomethacin—PTGR2—vagina—muscle cancer	0.00101	0.0166	CbGeAlD
Indomethacin—PPARA—embryo—muscle cancer	0.000992	0.0162	CbGeAlD
Indomethacin—PTGS2—hindlimb—muscle cancer	0.000979	0.016	CbGeAlD
Indomethacin—AKR1C3—Podofilox—Etoposide—muscle cancer	0.000974	0.301	CbGdCrCtD
Indomethacin—PTGR2—head—muscle cancer	0.000937	0.0153	CbGeAlD
Indomethacin—PTGR2—testis—muscle cancer	0.000905	0.0148	CbGeAlD
Indomethacin—GLO1—smooth muscle tissue—muscle cancer	0.000898	0.0147	CbGeAlD
Indomethacin—ABCC11—testis—muscle cancer	0.000896	0.0146	CbGeAlD
Indomethacin—Bromfenac—PTGS2—muscle cancer	0.000882	0.459	CrCbGaD
Indomethacin—GLO1—renal system—muscle cancer	0.000865	0.0141	CbGeAlD
Indomethacin—PTGS2—appendage—muscle cancer	0.00084	0.0137	CbGeAlD
Indomethacin—UGT1A9—renal system—muscle cancer	0.00084	0.0137	CbGeAlD
Indomethacin—PLA2G2A—smooth muscle tissue—muscle cancer	0.000835	0.0136	CbGeAlD
Indomethacin—CXCL8—smooth muscle tissue—muscle cancer	0.000827	0.0135	CbGeAlD
Indomethacin—PLA2G2A—renal system—muscle cancer	0.000804	0.0131	CbGeAlD
Indomethacin—ABCC6—renal system—muscle cancer	0.000796	0.013	CbGeAlD
Indomethacin—PPARA—smooth muscle tissue—muscle cancer	0.00078	0.0127	CbGeAlD
Indomethacin—GLO1—cardiac atrium—muscle cancer	0.000775	0.0127	CbGeAlD
Indomethacin—PPARA—renal system—muscle cancer	0.000751	0.0123	CbGeAlD
Indomethacin—SLC10A1—renal system—muscle cancer	0.000722	0.0118	CbGeAlD
Indomethacin—PLA2G2A—cardiac atrium—muscle cancer	0.00072	0.0118	CbGeAlD
Indomethacin—UGT2B7—renal system—muscle cancer	0.000677	0.0111	CbGeAlD
Indomethacin—GLO1—tendon—muscle cancer	0.000675	0.011	CbGeAlD
Indomethacin—AKR1C3—Vinblastine—Vincristine—muscle cancer	0.00067	0.207	CbGdCrCtD
Indomethacin—SLC22A11—renal system—muscle cancer	0.000659	0.0108	CbGeAlD
Indomethacin—GLO1—bone marrow—muscle cancer	0.000654	0.0107	CbGeAlD
Indomethacin—AKR1C3—smooth muscle tissue—muscle cancer	0.000648	0.0106	CbGeAlD
Indomethacin—SLC22A7—renal system—muscle cancer	0.000644	0.0105	CbGeAlD
Indomethacin—PLA2G2A—tendon—muscle cancer	0.000628	0.0103	CbGeAlD
Indomethacin—GLO1—vagina—muscle cancer	0.000626	0.0102	CbGeAlD
Indomethacin—CXCL8—bone marrow—muscle cancer	0.000602	0.00983	CbGeAlD
Indomethacin—Tolmetin—PTGS2—muscle cancer	0.000593	0.309	CrCbGaD
Indomethacin—GLO1—head—muscle cancer	0.000579	0.00945	CbGeAlD
Indomethacin—CXCL8—vagina—muscle cancer	0.000576	0.00942	CbGeAlD
Indomethacin—UGT1A1—renal system—muscle cancer	0.000575	0.0094	CbGeAlD
Indomethacin—GLO1—testis—muscle cancer	0.000559	0.00913	CbGeAlD
Indomethacin—AKR1C3—cardiac atrium—muscle cancer	0.000559	0.00913	CbGeAlD
Indomethacin—PPARG—embryo—muscle cancer	0.000546	0.00892	CbGeAlD
Indomethacin—PLA2G2A—head—muscle cancer	0.000538	0.00879	CbGeAlD
Indomethacin—ABCC6—head—muscle cancer	0.000533	0.0087	CbGeAlD
Indomethacin—PLA2G2A—testis—muscle cancer	0.00052	0.00849	CbGeAlD
Indomethacin—CXCL8—testis—muscle cancer	0.000514	0.00841	CbGeAlD
Indomethacin—PPARA—head—muscle cancer	0.000502	0.00821	CbGeAlD
Indomethacin—AKR1C3—tendon—muscle cancer	0.000487	0.00796	CbGeAlD
Indomethacin—PPARA—testis—muscle cancer	0.000485	0.00793	CbGeAlD
Indomethacin—SLC10A1—head—muscle cancer	0.000483	0.0079	CbGeAlD
Indomethacin—PPARG—Teniposide—Etoposide—muscle cancer	0.000479	0.148	CbGdCrCtD
Indomethacin—SLCO1B1—renal system—muscle cancer	0.000479	0.00782	CbGeAlD
Indomethacin—AKR1C3—bone marrow—muscle cancer	0.000472	0.00771	CbGeAlD
Indomethacin—SLC10A1—testis—muscle cancer	0.000467	0.00763	CbGeAlD
Indomethacin—ABCC3—renal system—muscle cancer	0.000454	0.00742	CbGeAlD
Indomethacin—AKR1C3—vagina—muscle cancer	0.000452	0.00739	CbGeAlD
Indomethacin—Naproxen—PTGS2—muscle cancer	0.000446	0.232	CrCbGaD
Indomethacin—UGT2B7—testis—muscle cancer	0.000437	0.00715	CbGeAlD
Indomethacin—PPARG—smooth muscle tissue—muscle cancer	0.000429	0.00701	CbGeAlD
Indomethacin—SLC22A7—testis—muscle cancer	0.000416	0.0068	CbGeAlD
Indomethacin—PPARG—renal system—muscle cancer	0.000413	0.00675	CbGeAlD
Indomethacin—AKR1C3—testis—muscle cancer	0.000403	0.00659	CbGeAlD
Indomethacin—SLCO1A2—renal system—muscle cancer	0.00039	0.00637	CbGeAlD
Indomethacin—ABCC4—renal system—muscle cancer	0.000375	0.00613	CbGeAlD
Indomethacin—CES1—head—muscle cancer	0.000373	0.00609	CbGeAlD
Indomethacin—SLC22A8—renal system—muscle cancer	0.000372	0.00608	CbGeAlD
Indomethacin—ABCC2—renal system—muscle cancer	0.000363	0.00593	CbGeAlD
Indomethacin—CES1—testis—muscle cancer	0.00036	0.00589	CbGeAlD
Indomethacin—PPARG—tendon—muscle cancer	0.000322	0.00527	CbGeAlD
Indomethacin—PPARG—bone marrow—muscle cancer	0.000312	0.0051	CbGeAlD
Indomethacin—ABCC3—head—muscle cancer	0.000304	0.00497	CbGeAlD
Indomethacin—PPARG—vagina—muscle cancer	0.000299	0.00489	CbGeAlD
Indomethacin—ABCC3—testis—muscle cancer	0.000294	0.0048	CbGeAlD
Indomethacin—ABCC4—tendon—muscle cancer	0.000293	0.00478	CbGeAlD
Indomethacin—ABCC1—cardiac atrium—muscle cancer	0.000286	0.00468	CbGeAlD
Indomethacin—ABCC4—bone marrow—muscle cancer	0.000284	0.00463	CbGeAlD
Indomethacin—ABCC2—tendon—muscle cancer	0.000283	0.00463	CbGeAlD
Indomethacin—PTGS2—embryo—muscle cancer	0.000279	0.00456	CbGeAlD
Indomethacin—PPARG—head—muscle cancer	0.000276	0.00451	CbGeAlD
Indomethacin—PPARG—testis—muscle cancer	0.000267	0.00436	CbGeAlD
Indomethacin—SLCO1A2—head—muscle cancer	0.000261	0.00426	CbGeAlD
Indomethacin—SLCO1A2—testis—muscle cancer	0.000252	0.00412	CbGeAlD
Indomethacin—ABCC4—head—muscle cancer	0.000251	0.0041	CbGeAlD
Indomethacin—ALB—testis—muscle cancer	0.00025	0.00409	CbGeAlD
Indomethacin—ABCC1—tendon—muscle cancer	0.00025	0.00408	CbGeAlD
Indomethacin—SLC22A8—head—muscle cancer	0.000249	0.00407	CbGeAlD
Indomethacin—ABCC4—testis—muscle cancer	0.000242	0.00396	CbGeAlD
Indomethacin—ABCC2—testis—muscle cancer	0.000235	0.00383	CbGeAlD
Indomethacin—ABCC1—vagina—muscle cancer	0.000232	0.00378	CbGeAlD
Indomethacin—PTGS1—smooth muscle tissue—muscle cancer	0.000229	0.00375	CbGeAlD
Indomethacin—CYP2C19—vagina—muscle cancer	0.000226	0.00369	CbGeAlD
Indomethacin—PTGS1—renal system—muscle cancer	0.000221	0.00361	CbGeAlD
Indomethacin—PTGS2—smooth muscle tissue—muscle cancer	0.000219	0.00358	CbGeAlD
Indomethacin—PTGS2—renal system—muscle cancer	0.000211	0.00345	CbGeAlD
Indomethacin—ABCC1—testis—muscle cancer	0.000207	0.00338	CbGeAlD
Indomethacin—PTGS1—cardiac atrium—muscle cancer	0.000198	0.00323	CbGeAlD
Indomethacin—Thrombophlebitis—Methotrexate—muscle cancer	0.000194	0.00268	CcSEcCtD
Indomethacin—Anaemia—Vincristine—muscle cancer	0.000192	0.00266	CcSEcCtD
Indomethacin—Colitis—Doxorubicin—muscle cancer	0.000192	0.00266	CcSEcCtD
Indomethacin—Skin exfoliation—Doxorubicin—muscle cancer	0.000191	0.00265	CcSEcCtD
Indomethacin—Oedema—Dactinomycin—muscle cancer	0.00019	0.00263	CcSEcCtD
Indomethacin—Fluid retention—Doxorubicin—muscle cancer	0.00019	0.00263	CcSEcCtD
Indomethacin—Aplastic anaemia—Doxorubicin—muscle cancer	0.000188	0.0026	CcSEcCtD
Indomethacin—Vertigo—Vincristine—muscle cancer	0.000187	0.00259	CcSEcCtD
Indomethacin—Leukopenia—Vincristine—muscle cancer	0.000186	0.00258	CcSEcCtD
Indomethacin—Thrombocytopenia—Dactinomycin—muscle cancer	0.000186	0.00258	CcSEcCtD
Indomethacin—Erythema multiforme—Etoposide—muscle cancer	0.000183	0.00254	CcSEcCtD
Indomethacin—Coma—Doxorubicin—muscle cancer	0.000183	0.00253	CcSEcCtD
Indomethacin—Anorexia—Dactinomycin—muscle cancer	0.000181	0.00251	CcSEcCtD
Indomethacin—Ecchymosis—Doxorubicin—muscle cancer	0.000181	0.00251	CcSEcCtD
Indomethacin—Mouth ulceration—Doxorubicin—muscle cancer	0.000181	0.00251	CcSEcCtD
Indomethacin—Convulsion—Vincristine—muscle cancer	0.00018	0.0025	CcSEcCtD
Indomethacin—Flushing—Etoposide—muscle cancer	0.00018	0.00249	CcSEcCtD
Indomethacin—Hypertension—Vincristine—muscle cancer	0.00018	0.00249	CcSEcCtD
Indomethacin—Pulmonary oedema—Doxorubicin—muscle cancer	0.000178	0.00247	CcSEcCtD
Indomethacin—Dermatitis exfoliative—Methotrexate—muscle cancer	0.000178	0.00246	CcSEcCtD
Indomethacin—ABCB1—embryo—muscle cancer	0.000172	0.00282	CbGeAlD
Indomethacin—PTGS1—tendon—muscle cancer	0.000172	0.00282	CbGeAlD
Indomethacin—Alopecia—Etoposide—muscle cancer	0.000171	0.00237	CcSEcCtD
Indomethacin—Anaphylactic shock—Vincristine—muscle cancer	0.00017	0.00235	CcSEcCtD
Indomethacin—Oedema—Vincristine—muscle cancer	0.00017	0.00235	CcSEcCtD
Indomethacin—Thrombophlebitis—Doxorubicin—muscle cancer	0.000168	0.00232	CcSEcCtD
Indomethacin—Osteoarthritis—Methotrexate—muscle cancer	0.000168	0.00232	CcSEcCtD
Indomethacin—Thrombocytopenia—Vincristine—muscle cancer	0.000166	0.0023	CcSEcCtD
Indomethacin—Decreased appetite—Dactinomycin—muscle cancer	0.000165	0.00229	CcSEcCtD
Indomethacin—PTGS2—tendon—muscle cancer	0.000165	0.00269	CbGeAlD
Indomethacin—Hyperhidrosis—Vincristine—muscle cancer	0.000164	0.00227	CcSEcCtD
Indomethacin—Fatigue—Dactinomycin—muscle cancer	0.000164	0.00227	CcSEcCtD
Indomethacin—Pain—Dactinomycin—muscle cancer	0.000162	0.00225	CcSEcCtD
Indomethacin—Vascular purpura—Doxorubicin—muscle cancer	0.000162	0.00225	CcSEcCtD
Indomethacin—Anorexia—Vincristine—muscle cancer	0.000162	0.00224	CcSEcCtD
Indomethacin—Eye pain—Doxorubicin—muscle cancer	0.000161	0.00223	CcSEcCtD
Indomethacin—Cardiac failure congestive—Doxorubicin—muscle cancer	0.00016	0.00222	CcSEcCtD
Indomethacin—PTGS1—vagina—muscle cancer	0.00016	0.00261	CbGeAlD
Indomethacin—PTGS2—bone marrow—muscle cancer	0.00016	0.00261	CbGeAlD
Indomethacin—Hypotension—Vincristine—muscle cancer	0.000159	0.0022	CcSEcCtD
Indomethacin—Feeling abnormal—Dactinomycin—muscle cancer	0.000157	0.00217	CcSEcCtD
Indomethacin—Ill-defined disorder—Etoposide—muscle cancer	0.000156	0.00217	CcSEcCtD
Indomethacin—Anaemia—Etoposide—muscle cancer	0.000156	0.00216	CcSEcCtD
Indomethacin—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000155	0.00215	CcSEcCtD
Indomethacin—Hot flush—Doxorubicin—muscle cancer	0.000155	0.00215	CcSEcCtD
Indomethacin—Menopausal symptoms—Doxorubicin—muscle cancer	0.000154	0.00213	CcSEcCtD
Indomethacin—Dermatitis exfoliative—Doxorubicin—muscle cancer	0.000154	0.00213	CcSEcCtD
Indomethacin—Insomnia—Vincristine—muscle cancer	0.000153	0.00213	CcSEcCtD
Indomethacin—PTGS2—vagina—muscle cancer	0.000153	0.0025	CbGeAlD
Indomethacin—Renal impairment—Doxorubicin—muscle cancer	0.000152	0.00211	CcSEcCtD
Indomethacin—Paraesthesia—Vincristine—muscle cancer	0.000152	0.00211	CcSEcCtD
Indomethacin—Malaise—Etoposide—muscle cancer	0.000152	0.00211	CcSEcCtD
Indomethacin—Vertigo—Etoposide—muscle cancer	0.000151	0.0021	CcSEcCtD
Indomethacin—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.000151	0.00209	CcSEcCtD
Indomethacin—Leukopenia—Etoposide—muscle cancer	0.000151	0.00209	CcSEcCtD
Indomethacin—Purpura—Doxorubicin—muscle cancer	0.000151	0.00209	CcSEcCtD
Indomethacin—Abdominal pain—Dactinomycin—muscle cancer	0.00015	0.00208	CcSEcCtD
Indomethacin—Body temperature increased—Dactinomycin—muscle cancer	0.00015	0.00208	CcSEcCtD
Indomethacin—Hypoglycaemia—Doxorubicin—muscle cancer	0.000149	0.00206	CcSEcCtD
Indomethacin—Loss of consciousness—Etoposide—muscle cancer	0.000148	0.00205	CcSEcCtD
Indomethacin—PTGS1—head—muscle cancer	0.000148	0.00241	CbGeAlD
Indomethacin—Decreased appetite—Vincristine—muscle cancer	0.000148	0.00205	CcSEcCtD
Indomethacin—Fatigue—Vincristine—muscle cancer	0.000146	0.00203	CcSEcCtD
Indomethacin—Convulsion—Etoposide—muscle cancer	0.000146	0.00202	CcSEcCtD
Indomethacin—Hyponatraemia—Doxorubicin—muscle cancer	0.000146	0.00202	CcSEcCtD
Indomethacin—Hypertension—Etoposide—muscle cancer	0.000145	0.00202	CcSEcCtD
Indomethacin—Pain—Vincristine—muscle cancer	0.000145	0.00201	CcSEcCtD
Indomethacin—Constipation—Vincristine—muscle cancer	0.000145	0.00201	CcSEcCtD
Indomethacin—Diplopia—Doxorubicin—muscle cancer	0.000145	0.00201	CcSEcCtD
Indomethacin—Osteoarthritis—Doxorubicin—muscle cancer	0.000145	0.00201	CcSEcCtD
Indomethacin—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	0.000145	0.00201	CcSEcCtD
Indomethacin—Asthma—Methotrexate—muscle cancer	0.000145	0.00201	CcSEcCtD
Indomethacin—Chest pain—Etoposide—muscle cancer	0.000143	0.00199	CcSEcCtD
Indomethacin—PTGS1—testis—muscle cancer	0.000143	0.00233	CbGeAlD
Indomethacin—Discomfort—Etoposide—muscle cancer	0.000142	0.00196	CcSEcCtD
Indomethacin—PTGS2—head—muscle cancer	0.000141	0.00231	CbGeAlD
Indomethacin—Hypersensitivity—Dactinomycin—muscle cancer	0.00014	0.00194	CcSEcCtD
Indomethacin—Abdominal discomfort—Methotrexate—muscle cancer	0.000139	0.00192	CcSEcCtD
Indomethacin—Gastrointestinal pain—Vincristine—muscle cancer	0.000139	0.00192	CcSEcCtD
Indomethacin—Confusional state—Etoposide—muscle cancer	0.000139	0.00192	CcSEcCtD
Indomethacin—Pancytopenia—Methotrexate—muscle cancer	0.000138	0.00191	CcSEcCtD
Indomethacin—Anaphylactic shock—Etoposide—muscle cancer	0.000137	0.00191	CcSEcCtD
Indomethacin—Asthenia—Dactinomycin—muscle cancer	0.000136	0.00189	CcSEcCtD
Indomethacin—Thrombocytopenia—Etoposide—muscle cancer	0.000135	0.00187	CcSEcCtD
Indomethacin—Tachycardia—Etoposide—muscle cancer	0.000134	0.00186	CcSEcCtD
Indomethacin—Body temperature increased—Vincristine—muscle cancer	0.000134	0.00186	CcSEcCtD
Indomethacin—Abdominal pain—Vincristine—muscle cancer	0.000134	0.00186	CcSEcCtD
Indomethacin—Hyperhidrosis—Etoposide—muscle cancer	0.000133	0.00184	CcSEcCtD
Indomethacin—Abdominal pain upper—Doxorubicin—muscle cancer	0.000132	0.00184	CcSEcCtD
Indomethacin—Anorexia—Etoposide—muscle cancer	0.000131	0.00182	CcSEcCtD
Indomethacin—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.000131	0.00181	CcSEcCtD
Indomethacin—ABCB1—renal system—muscle cancer	0.000131	0.00213	CbGeAlD
Indomethacin—Diarrhoea—Dactinomycin—muscle cancer	0.00013	0.0018	CcSEcCtD
Indomethacin—Drowsiness—Methotrexate—muscle cancer	0.000129	0.00179	CcSEcCtD
Indomethacin—Depression—Methotrexate—muscle cancer	0.000129	0.00178	CcSEcCtD
Indomethacin—Hypotension—Etoposide—muscle cancer	0.000128	0.00178	CcSEcCtD
Indomethacin—Gastritis—Doxorubicin—muscle cancer	0.000128	0.00178	CcSEcCtD
Indomethacin—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000128	0.00177	CcSEcCtD
Indomethacin—Muscular weakness—Doxorubicin—muscle cancer	0.000128	0.00177	CcSEcCtD
Indomethacin—Renal failure—Methotrexate—muscle cancer	0.000127	0.00176	CcSEcCtD
Indomethacin—Abdominal distension—Doxorubicin—muscle cancer	0.000126	0.00175	CcSEcCtD
Indomethacin—Stomatitis—Methotrexate—muscle cancer	0.000126	0.00174	CcSEcCtD
Indomethacin—Asthma—Doxorubicin—muscle cancer	0.000125	0.00174	CcSEcCtD
Indomethacin—Hypersensitivity—Vincristine—muscle cancer	0.000125	0.00173	CcSEcCtD
Indomethacin—Sweating—Methotrexate—muscle cancer	0.000124	0.00172	CcSEcCtD
Indomethacin—Paraesthesia—Etoposide—muscle cancer	0.000123	0.00171	CcSEcCtD
Indomethacin—Haematuria—Methotrexate—muscle cancer	0.000123	0.00171	CcSEcCtD
Indomethacin—Dyspnoea—Etoposide—muscle cancer	0.000123	0.0017	CcSEcCtD
Indomethacin—Somnolence—Etoposide—muscle cancer	0.000122	0.00169	CcSEcCtD
Indomethacin—Epistaxis—Methotrexate—muscle cancer	0.000122	0.00169	CcSEcCtD
Indomethacin—Asthenia—Vincristine—muscle cancer	0.000122	0.00169	CcSEcCtD
Indomethacin—Vomiting—Dactinomycin—muscle cancer	0.000121	0.00167	CcSEcCtD
Indomethacin—Agranulocytosis—Methotrexate—muscle cancer	0.00012	0.00167	CcSEcCtD
Indomethacin—Rash—Dactinomycin—muscle cancer	0.00012	0.00166	CcSEcCtD
Indomethacin—Decreased appetite—Etoposide—muscle cancer	0.00012	0.00166	CcSEcCtD
Indomethacin—Pancytopenia—Doxorubicin—muscle cancer	0.000119	0.00165	CcSEcCtD
Indomethacin—Fatigue—Etoposide—muscle cancer	0.000119	0.00164	CcSEcCtD
Indomethacin—Pain—Etoposide—muscle cancer	0.000118	0.00163	CcSEcCtD
Indomethacin—Constipation—Etoposide—muscle cancer	0.000118	0.00163	CcSEcCtD
Indomethacin—Haemoglobin—Methotrexate—muscle cancer	0.000116	0.00162	CcSEcCtD
Indomethacin—Diarrhoea—Vincristine—muscle cancer	0.000116	0.00161	CcSEcCtD
Indomethacin—Hepatitis—Methotrexate—muscle cancer	0.000116	0.00161	CcSEcCtD
Indomethacin—Haemorrhage—Methotrexate—muscle cancer	0.000116	0.00161	CcSEcCtD
Indomethacin—Pollakiuria—Doxorubicin—muscle cancer	0.000116	0.00161	CcSEcCtD
Indomethacin—Weight increased—Doxorubicin—muscle cancer	0.000114	0.00158	CcSEcCtD
Indomethacin—Feeling abnormal—Etoposide—muscle cancer	0.000113	0.00157	CcSEcCtD
Indomethacin—Hyperglycaemia—Doxorubicin—muscle cancer	0.000113	0.00157	CcSEcCtD
Indomethacin—Nausea—Dactinomycin—muscle cancer	0.000113	0.00156	CcSEcCtD
Indomethacin—Gastrointestinal pain—Etoposide—muscle cancer	0.000112	0.00156	CcSEcCtD
Indomethacin—Dizziness—Vincristine—muscle cancer	0.000112	0.00156	CcSEcCtD
Indomethacin—Drowsiness—Doxorubicin—muscle cancer	0.000112	0.00155	CcSEcCtD
Indomethacin—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000111	0.00154	CcSEcCtD
Indomethacin—Renal failure—Doxorubicin—muscle cancer	0.00011	0.00152	CcSEcCtD
Indomethacin—Erythema multiforme—Methotrexate—muscle cancer	0.00011	0.00152	CcSEcCtD
Indomethacin—Neuropathy peripheral—Doxorubicin—muscle cancer	0.00011	0.00152	CcSEcCtD
Indomethacin—Urticaria—Etoposide—muscle cancer	0.000109	0.00151	CcSEcCtD
Indomethacin—Stomatitis—Doxorubicin—muscle cancer	0.000109	0.00151	CcSEcCtD
Indomethacin—Jaundice—Doxorubicin—muscle cancer	0.000109	0.00151	CcSEcCtD
Indomethacin—Body temperature increased—Etoposide—muscle cancer	0.000109	0.00151	CcSEcCtD
Indomethacin—Abdominal pain—Etoposide—muscle cancer	0.000109	0.00151	CcSEcCtD
Indomethacin—Tinnitus—Methotrexate—muscle cancer	0.000108	0.0015	CcSEcCtD
Indomethacin—Vomiting—Vincristine—muscle cancer	0.000108	0.0015	CcSEcCtD
Indomethacin—Sweating—Doxorubicin—muscle cancer	0.000107	0.00149	CcSEcCtD
Indomethacin—Rash—Vincristine—muscle cancer	0.000107	0.00148	CcSEcCtD
Indomethacin—Dermatitis—Vincristine—muscle cancer	0.000107	0.00148	CcSEcCtD
Indomethacin—Haematuria—Doxorubicin—muscle cancer	0.000107	0.00148	CcSEcCtD
Indomethacin—Headache—Vincristine—muscle cancer	0.000106	0.00147	CcSEcCtD
Indomethacin—Epistaxis—Doxorubicin—muscle cancer	0.000105	0.00146	CcSEcCtD
Indomethacin—Agranulocytosis—Doxorubicin—muscle cancer	0.000104	0.00145	CcSEcCtD
Indomethacin—Alopecia—Methotrexate—muscle cancer	0.000102	0.00142	CcSEcCtD
Indomethacin—Bradycardia—Doxorubicin—muscle cancer	0.000102	0.00142	CcSEcCtD
Indomethacin—Hypersensitivity—Etoposide—muscle cancer	0.000101	0.0014	CcSEcCtD
Indomethacin—Erythema—Methotrexate—muscle cancer	0.000101	0.0014	CcSEcCtD
Indomethacin—Haemoglobin—Doxorubicin—muscle cancer	0.000101	0.0014	CcSEcCtD
Indomethacin—Nausea—Vincristine—muscle cancer	0.000101	0.0014	CcSEcCtD
Indomethacin—Hepatitis—Doxorubicin—muscle cancer	0.0001	0.00139	CcSEcCtD
Indomethacin—Haemorrhage—Doxorubicin—muscle cancer	0.0001	0.00139	CcSEcCtD
Indomethacin—ABCB1—bone marrow—muscle cancer	9.87e-05	0.00161	CbGeAlD
Indomethacin—Asthenia—Etoposide—muscle cancer	9.86e-05	0.00137	CcSEcCtD
Indomethacin—Pruritus—Etoposide—muscle cancer	9.73e-05	0.00135	CcSEcCtD
Indomethacin—Vision blurred—Methotrexate—muscle cancer	9.51e-05	0.00132	CcSEcCtD
Indomethacin—Erythema multiforme—Doxorubicin—muscle cancer	9.49e-05	0.00132	CcSEcCtD
Indomethacin—ABCB1—vagina—muscle cancer	9.45e-05	0.00154	CbGeAlD
Indomethacin—Diarrhoea—Etoposide—muscle cancer	9.41e-05	0.0013	CcSEcCtD
Indomethacin—Ill-defined disorder—Methotrexate—muscle cancer	9.36e-05	0.0013	CcSEcCtD
Indomethacin—Tinnitus—Doxorubicin—muscle cancer	9.36e-05	0.0013	CcSEcCtD
Indomethacin—Anaemia—Methotrexate—muscle cancer	9.33e-05	0.00129	CcSEcCtD
Indomethacin—Flushing—Doxorubicin—muscle cancer	9.31e-05	0.00129	CcSEcCtD
Indomethacin—Malaise—Methotrexate—muscle cancer	9.1e-05	0.00126	CcSEcCtD
Indomethacin—Dizziness—Etoposide—muscle cancer	9.09e-05	0.00126	CcSEcCtD
Indomethacin—Vertigo—Methotrexate—muscle cancer	9.06e-05	0.00126	CcSEcCtD
Indomethacin—Leukopenia—Methotrexate—muscle cancer	9.03e-05	0.00125	CcSEcCtD
Indomethacin—Arrhythmia—Doxorubicin—muscle cancer	8.97e-05	0.00124	CcSEcCtD
Indomethacin—PLA2G2A—Metabolism of lipids and lipoproteins—MED12—muscle cancer	8.89e-05	0.00425	CbGpPWpGaD
Indomethacin—Alopecia—Doxorubicin—muscle cancer	8.87e-05	0.00123	CcSEcCtD
Indomethacin—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	8.74e-05	0.00418	CbGpPWpGaD
Indomethacin—Convulsion—Methotrexate—muscle cancer	8.74e-05	0.00121	CcSEcCtD
Indomethacin—Vomiting—Etoposide—muscle cancer	8.74e-05	0.00121	CcSEcCtD
Indomethacin—Erythema—Doxorubicin—muscle cancer	8.74e-05	0.00121	CcSEcCtD
Indomethacin—ABCB1—head—muscle cancer	8.73e-05	0.00143	CbGeAlD
Indomethacin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	8.72e-05	0.00417	CbGpPWpGaD
Indomethacin—Rash—Etoposide—muscle cancer	8.67e-05	0.0012	CcSEcCtD
Indomethacin—Dermatitis—Etoposide—muscle cancer	8.66e-05	0.0012	CcSEcCtD
Indomethacin—Headache—Etoposide—muscle cancer	8.61e-05	0.00119	CcSEcCtD
Indomethacin—Flatulence—Doxorubicin—muscle cancer	8.61e-05	0.00119	CcSEcCtD
Indomethacin—Chest pain—Methotrexate—muscle cancer	8.59e-05	0.00119	CcSEcCtD
Indomethacin—Tension—Doxorubicin—muscle cancer	8.57e-05	0.00119	CcSEcCtD
Indomethacin—PTGS2—S1P1 pathway—VEGFA—muscle cancer	8.53e-05	0.00408	CbGpPWpGaD
Indomethacin—Discomfort—Methotrexate—muscle cancer	8.49e-05	0.00118	CcSEcCtD
Indomethacin—Nervousness—Doxorubicin—muscle cancer	8.49e-05	0.00118	CcSEcCtD
Indomethacin—ABCB1—testis—muscle cancer	8.44e-05	0.00138	CbGeAlD
Indomethacin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—muscle cancer	8.37e-05	0.004	CbGpPWpGaD
Indomethacin—Confusional state—Methotrexate—muscle cancer	8.3e-05	0.00115	CcSEcCtD
Indomethacin—Anaphylactic shock—Methotrexate—muscle cancer	8.23e-05	0.00114	CcSEcCtD
Indomethacin—Vision blurred—Doxorubicin—muscle cancer	8.23e-05	0.00114	CcSEcCtD
Indomethacin—CYP2C9—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	8.17e-05	0.0039	CbGpPWpGaD
Indomethacin—Nausea—Etoposide—muscle cancer	8.17e-05	0.00113	CcSEcCtD
Indomethacin—Ill-defined disorder—Doxorubicin—muscle cancer	8.11e-05	0.00112	CcSEcCtD
Indomethacin—Anaemia—Doxorubicin—muscle cancer	8.07e-05	0.00112	CcSEcCtD
Indomethacin—Thrombocytopenia—Methotrexate—muscle cancer	8.06e-05	0.00112	CcSEcCtD
Indomethacin—PPARG—Developmental Biology—MYOG—muscle cancer	8.01e-05	0.00383	CbGpPWpGaD
Indomethacin—Hyperhidrosis—Methotrexate—muscle cancer	7.96e-05	0.0011	CcSEcCtD
Indomethacin—CXCL8—Glucocorticoid receptor regulatory network—MDM2—muscle cancer	7.96e-05	0.0038	CbGpPWpGaD
Indomethacin—ABCC3—Fluoropyrimidine Activity—TP53—muscle cancer	7.88e-05	0.00377	CbGpPWpGaD
Indomethacin—Malaise—Doxorubicin—muscle cancer	7.88e-05	0.00109	CcSEcCtD
Indomethacin—CXCL8—Cellular responses to stress—HMGA1—muscle cancer	7.86e-05	0.00376	CbGpPWpGaD
Indomethacin—Vertigo—Doxorubicin—muscle cancer	7.85e-05	0.00109	CcSEcCtD
Indomethacin—Anorexia—Methotrexate—muscle cancer	7.85e-05	0.00109	CcSEcCtD
Indomethacin—Syncope—Doxorubicin—muscle cancer	7.83e-05	0.00109	CcSEcCtD
Indomethacin—Leukopenia—Doxorubicin—muscle cancer	7.82e-05	0.00108	CcSEcCtD
Indomethacin—Palpitations—Doxorubicin—muscle cancer	7.72e-05	0.00107	CcSEcCtD
Indomethacin—Hypotension—Methotrexate—muscle cancer	7.69e-05	0.00107	CcSEcCtD
Indomethacin—PPARG—Regulation of retinoblastoma protein—CDKN2A—muscle cancer	7.69e-05	0.00368	CbGpPWpGaD
Indomethacin—Loss of consciousness—Doxorubicin—muscle cancer	7.68e-05	0.00106	CcSEcCtD
Indomethacin—CXCL8—G alpha (i) signalling events—CNR1—muscle cancer	7.59e-05	0.00363	CbGpPWpGaD
Indomethacin—Convulsion—Doxorubicin—muscle cancer	7.57e-05	0.00105	CcSEcCtD
Indomethacin—SLC10A1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	7.56e-05	0.00362	CbGpPWpGaD
Indomethacin—Hypertension—Doxorubicin—muscle cancer	7.54e-05	0.00105	CcSEcCtD
Indomethacin—PPARG—Regulation of retinoblastoma protein—MDM2—muscle cancer	7.46e-05	0.00357	CbGpPWpGaD
Indomethacin—Insomnia—Methotrexate—muscle cancer	7.45e-05	0.00103	CcSEcCtD
Indomethacin—ABCC1—Arachidonic acid metabolism—PTGS2—muscle cancer	7.44e-05	0.00356	CbGpPWpGaD
Indomethacin—Chest pain—Doxorubicin—muscle cancer	7.44e-05	0.00103	CcSEcCtD
Indomethacin—Anxiety—Doxorubicin—muscle cancer	7.41e-05	0.00103	CcSEcCtD
Indomethacin—ABCC4—Fluoropyrimidine Activity—TP53—muscle cancer	7.41e-05	0.00354	CbGpPWpGaD
Indomethacin—Paraesthesia—Methotrexate—muscle cancer	7.39e-05	0.00103	CcSEcCtD
Indomethacin—Discomfort—Doxorubicin—muscle cancer	7.35e-05	0.00102	CcSEcCtD
Indomethacin—Dyspnoea—Methotrexate—muscle cancer	7.34e-05	0.00102	CcSEcCtD
Indomethacin—Somnolence—Methotrexate—muscle cancer	7.32e-05	0.00101	CcSEcCtD
Indomethacin—Dyspepsia—Methotrexate—muscle cancer	7.25e-05	0.00101	CcSEcCtD
Indomethacin—PPARG—Adipogenesis—FOXO1—muscle cancer	7.23e-05	0.00345	CbGpPWpGaD
Indomethacin—Confusional state—Doxorubicin—muscle cancer	7.19e-05	0.000997	CcSEcCtD
Indomethacin—PTGDR2—Signaling by GPCR—PTCH1—muscle cancer	7.17e-05	0.00343	CbGpPWpGaD
Indomethacin—Decreased appetite—Methotrexate—muscle cancer	7.16e-05	0.000992	CcSEcCtD
Indomethacin—Anaphylactic shock—Doxorubicin—muscle cancer	7.13e-05	0.000989	CcSEcCtD
Indomethacin—Oedema—Doxorubicin—muscle cancer	7.13e-05	0.000989	CcSEcCtD
Indomethacin—Fatigue—Methotrexate—muscle cancer	7.1e-05	0.000984	CcSEcCtD
Indomethacin—Pain—Methotrexate—muscle cancer	7.04e-05	0.000976	CcSEcCtD
Indomethacin—Shock—Doxorubicin—muscle cancer	7.01e-05	0.000973	CcSEcCtD
Indomethacin—PLA2G2A—Metabolism—FH—muscle cancer	7.01e-05	0.00335	CbGpPWpGaD
Indomethacin—Thrombocytopenia—Doxorubicin—muscle cancer	6.98e-05	0.000968	CcSEcCtD
Indomethacin—Tachycardia—Doxorubicin—muscle cancer	6.96e-05	0.000965	CcSEcCtD
Indomethacin—PPARA—Developmental Biology—MYOD1—muscle cancer	6.9e-05	0.0033	CbGpPWpGaD
Indomethacin—Hyperhidrosis—Doxorubicin—muscle cancer	6.89e-05	0.000956	CcSEcCtD
Indomethacin—Anorexia—Doxorubicin—muscle cancer	6.8e-05	0.000942	CcSEcCtD
Indomethacin—Feeling abnormal—Methotrexate—muscle cancer	6.79e-05	0.000941	CcSEcCtD
Indomethacin—Gastrointestinal pain—Methotrexate—muscle cancer	6.73e-05	0.000934	CcSEcCtD
Indomethacin—CXCL8—Senescence-Associated Secretory Phenotype (SASP)—CDKN2A—muscle cancer	6.73e-05	0.00322	CbGpPWpGaD
Indomethacin—CXCL8—Senescence and Autophagy in Cancer—CDKN2A—muscle cancer	6.73e-05	0.00322	CbGpPWpGaD
Indomethacin—PPARA—Generic Transcription Pathway—MED12—muscle cancer	6.71e-05	0.00321	CbGpPWpGaD
Indomethacin—PTGDR2—GPCR downstream signaling—CNR1—muscle cancer	6.67e-05	0.00319	CbGpPWpGaD
Indomethacin—Hypotension—Doxorubicin—muscle cancer	6.66e-05	0.000924	CcSEcCtD
Indomethacin—Urticaria—Methotrexate—muscle cancer	6.54e-05	0.000907	CcSEcCtD
Indomethacin—CXCL8—Senescence and Autophagy in Cancer—MDM2—muscle cancer	6.53e-05	0.00312	CbGpPWpGaD
Indomethacin—Abdominal pain—Methotrexate—muscle cancer	6.51e-05	0.000903	CcSEcCtD
Indomethacin—Body temperature increased—Methotrexate—muscle cancer	6.51e-05	0.000903	CcSEcCtD
Indomethacin—AKR1C3—Metabolism of lipids and lipoproteins—MED12—muscle cancer	6.5e-05	0.00311	CbGpPWpGaD
Indomethacin—Insomnia—Doxorubicin—muscle cancer	6.45e-05	0.000894	CcSEcCtD
Indomethacin—Paraesthesia—Doxorubicin—muscle cancer	6.4e-05	0.000888	CcSEcCtD
Indomethacin—Dyspnoea—Doxorubicin—muscle cancer	6.36e-05	0.000881	CcSEcCtD
Indomethacin—Somnolence—Doxorubicin—muscle cancer	6.34e-05	0.000879	CcSEcCtD
Indomethacin—PPARA—Developmental Biology—MED12—muscle cancer	6.31e-05	0.00302	CbGpPWpGaD
Indomethacin—PTGS1—Arachidonic acid metabolism—PTGS2—muscle cancer	6.29e-05	0.00301	CbGpPWpGaD
Indomethacin—Dyspepsia—Doxorubicin—muscle cancer	6.28e-05	0.00087	CcSEcCtD
Indomethacin—CXCL8—Allograft Rejection—VEGFA—muscle cancer	6.23e-05	0.00298	CbGpPWpGaD
Indomethacin—Decreased appetite—Doxorubicin—muscle cancer	6.2e-05	0.000859	CcSEcCtD
Indomethacin—Fatigue—Doxorubicin—muscle cancer	6.15e-05	0.000852	CcSEcCtD
Indomethacin—Pain—Doxorubicin—muscle cancer	6.1e-05	0.000845	CcSEcCtD
Indomethacin—Constipation—Doxorubicin—muscle cancer	6.1e-05	0.000845	CcSEcCtD
Indomethacin—Hypersensitivity—Methotrexate—muscle cancer	6.07e-05	0.000841	CcSEcCtD
Indomethacin—PTGDR2—Signaling by GPCR—CNR1—muscle cancer	6.06e-05	0.00289	CbGpPWpGaD
Indomethacin—CXCL8—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	6.04e-05	0.00289	CbGpPWpGaD
Indomethacin—SLC10A1—Metabolism—FH—muscle cancer	5.96e-05	0.00285	CbGpPWpGaD
Indomethacin—PLA2G2A—Spinal Cord Injury—TP53—muscle cancer	5.92e-05	0.00283	CbGpPWpGaD
Indomethacin—Asthenia—Methotrexate—muscle cancer	5.91e-05	0.000819	CcSEcCtD
Indomethacin—Feeling abnormal—Doxorubicin—muscle cancer	5.88e-05	0.000815	CcSEcCtD
Indomethacin—Gastrointestinal pain—Doxorubicin—muscle cancer	5.83e-05	0.000808	CcSEcCtD
Indomethacin—Pruritus—Methotrexate—muscle cancer	5.83e-05	0.000808	CcSEcCtD
Indomethacin—CXCL8—Spinal Cord Injury—PTGS2—muscle cancer	5.73e-05	0.00274	CbGpPWpGaD
Indomethacin—Urticaria—Doxorubicin—muscle cancer	5.66e-05	0.000785	CcSEcCtD
Indomethacin—PPARA—Metabolism of lipids and lipoproteins—MED12—muscle cancer	5.64e-05	0.0027	CbGpPWpGaD
Indomethacin—Abdominal pain—Doxorubicin—muscle cancer	5.64e-05	0.000782	CcSEcCtD
Indomethacin—Body temperature increased—Doxorubicin—muscle cancer	5.64e-05	0.000782	CcSEcCtD
Indomethacin—Diarrhoea—Methotrexate—muscle cancer	5.63e-05	0.000781	CcSEcCtD
Indomethacin—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	5.47e-05	0.00262	CbGpPWpGaD
Indomethacin—CXCL8—GPCR ligand binding—PTCH1—muscle cancer	5.45e-05	0.0026	CbGpPWpGaD
Indomethacin—Dizziness—Methotrexate—muscle cancer	5.45e-05	0.000755	CcSEcCtD
Indomethacin—ABCC4—Hemostasis—ANGPT2—muscle cancer	5.41e-05	0.00259	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—KIDINS220—muscle cancer	5.32e-05	0.00254	CbGpPWpGaD
Indomethacin—Hypersensitivity—Doxorubicin—muscle cancer	5.25e-05	0.000728	CcSEcCtD
Indomethacin—Vomiting—Methotrexate—muscle cancer	5.24e-05	0.000726	CcSEcCtD
Indomethacin—ALB—Platelet degranulation—IGF2—muscle cancer	5.21e-05	0.00249	CbGpPWpGaD
Indomethacin—Rash—Methotrexate—muscle cancer	5.19e-05	0.00072	CcSEcCtD
Indomethacin—Dermatitis—Methotrexate—muscle cancer	5.19e-05	0.000719	CcSEcCtD
Indomethacin—CXCL8—AP-1 transcription factor network—TP53—muscle cancer	5.18e-05	0.00248	CbGpPWpGaD
Indomethacin—Headache—Methotrexate—muscle cancer	5.16e-05	0.000715	CcSEcCtD
Indomethacin—AKR1C3—Metabolism—FH—muscle cancer	5.13e-05	0.00245	CbGpPWpGaD
Indomethacin—Asthenia—Doxorubicin—muscle cancer	5.12e-05	0.000709	CcSEcCtD
Indomethacin—ABCC4—Platelet activation, signaling and aggregation—IGF2—muscle cancer	5.11e-05	0.00244	CbGpPWpGaD
Indomethacin—Pruritus—Doxorubicin—muscle cancer	5.04e-05	0.000699	CcSEcCtD
Indomethacin—ALB—Response to elevated platelet cytosolic Ca2+—IGF2—muscle cancer	4.96e-05	0.00237	CbGpPWpGaD
Indomethacin—PPARG—Developmental Biology—MYOD1—muscle cancer	4.95e-05	0.00237	CbGpPWpGaD
Indomethacin—Nausea—Methotrexate—muscle cancer	4.89e-05	0.000678	CcSEcCtD
Indomethacin—Diarrhoea—Doxorubicin—muscle cancer	4.88e-05	0.000676	CcSEcCtD
Indomethacin—ABCC4—Platelet degranulation—VEGFA—muscle cancer	4.83e-05	0.00231	CbGpPWpGaD
Indomethacin—PPARG—Generic Transcription Pathway—MED12—muscle cancer	4.81e-05	0.0023	CbGpPWpGaD
Indomethacin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—muscle cancer	4.78e-05	0.00228	CbGpPWpGaD
Indomethacin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	4.74e-05	0.00226	CbGpPWpGaD
Indomethacin—Dizziness—Doxorubicin—muscle cancer	4.71e-05	0.000654	CcSEcCtD
Indomethacin—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—muscle cancer	4.6e-05	0.0022	CbGpPWpGaD
Indomethacin—CXCL8—GPCR ligand binding—CNR1—muscle cancer	4.6e-05	0.0022	CbGpPWpGaD
Indomethacin—CXCL8—Glucocorticoid receptor regulatory network—TP53—muscle cancer	4.57e-05	0.00218	CbGpPWpGaD
Indomethacin—Vomiting—Doxorubicin—muscle cancer	4.53e-05	0.000629	CcSEcCtD
Indomethacin—PPARG—Developmental Biology—MED12—muscle cancer	4.52e-05	0.00216	CbGpPWpGaD
Indomethacin—Rash—Doxorubicin—muscle cancer	4.5e-05	0.000623	CcSEcCtD
Indomethacin—Dermatitis—Doxorubicin—muscle cancer	4.49e-05	0.000623	CcSEcCtD
Indomethacin—Headache—Doxorubicin—muscle cancer	4.47e-05	0.000619	CcSEcCtD
Indomethacin—PPARA—Metabolism—FH—muscle cancer	4.44e-05	0.00212	CbGpPWpGaD
Indomethacin—PTGS2—C-MYB transcription factor network—KIT—muscle cancer	4.34e-05	0.00208	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism of lipids and lipoproteins—MED12—muscle cancer	4.27e-05	0.00204	CbGpPWpGaD
Indomethacin—CXCL8—Cellular Senescence—CDKN2A—muscle cancer	4.26e-05	0.00204	CbGpPWpGaD
Indomethacin—PTGDR2—Signaling Pathways—PTCH1—muscle cancer	4.24e-05	0.00203	CbGpPWpGaD
Indomethacin—Nausea—Doxorubicin—muscle cancer	4.24e-05	0.000587	CcSEcCtD
Indomethacin—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	4.2e-05	0.00201	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—KIDINS220—muscle cancer	4.19e-05	0.00201	CbGpPWpGaD
Indomethacin—CXCL8—Cellular Senescence—MDM2—muscle cancer	4.13e-05	0.00198	CbGpPWpGaD
Indomethacin—PPARG—Metabolism of lipids and lipoproteins—MED12—muscle cancer	4.04e-05	0.00193	CbGpPWpGaD
Indomethacin—PTGS1—Selenium Micronutrient Network—PTGS2—muscle cancer	4e-05	0.00191	CbGpPWpGaD
Indomethacin—PTGS2—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	4e-05	0.00191	CbGpPWpGaD
Indomethacin—PLA2G2A—Metabolism—MED12—muscle cancer	3.96e-05	0.00189	CbGpPWpGaD
Indomethacin—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—muscle cancer	3.95e-05	0.00189	CbGpPWpGaD
Indomethacin—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	3.88e-05	0.00185	CbGpPWpGaD
Indomethacin—CXCL8—Senescence and Autophagy in Cancer—TP53—muscle cancer	3.75e-05	0.00179	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	3.72e-05	0.00178	CbGpPWpGaD
Indomethacin—PTGDR2—Signaling Pathways—FOXO4—muscle cancer	3.64e-05	0.00174	CbGpPWpGaD
Indomethacin—CYP2C19—Arachidonic acid metabolism—PTGS2—muscle cancer	3.63e-05	0.00173	CbGpPWpGaD
Indomethacin—CXCL8—SIDS Susceptibility Pathways—VEGFA—muscle cancer	3.61e-05	0.00173	CbGpPWpGaD
Indomethacin—PLA2G2A—Metabolism—ENO2—muscle cancer	3.61e-05	0.00173	CbGpPWpGaD
Indomethacin—PTGDR2—Signaling Pathways—CNR1—muscle cancer	3.58e-05	0.00171	CbGpPWpGaD
Indomethacin—PTGS2—C-MYB transcription factor network—CDKN2A—muscle cancer	3.53e-05	0.00169	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	3.47e-05	0.00166	CbGpPWpGaD
Indomethacin—PPARA—Developmental Biology—FOXO1—muscle cancer	3.47e-05	0.00166	CbGpPWpGaD
Indomethacin—CXCL8—Spinal Cord Injury—TP53—muscle cancer	3.41e-05	0.00163	CbGpPWpGaD
Indomethacin—SLC10A1—Metabolism—MED12—muscle cancer	3.37e-05	0.00161	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism—FH—muscle cancer	3.37e-05	0.00161	CbGpPWpGaD
Indomethacin—UGT2B7—Metabolism—FH—muscle cancer	3.37e-05	0.00161	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	3.35e-05	0.0016	CbGpPWpGaD
Indomethacin—CYP2C9—Arachidonic acid metabolism—PTGS2—muscle cancer	3.31e-05	0.00158	CbGpPWpGaD
Indomethacin—PPARA—Gene Expression—MED12—muscle cancer	3.23e-05	0.00154	CbGpPWpGaD
Indomethacin—CXCL8—Cellular responses to stress—CDKN2A—muscle cancer	3.22e-05	0.00154	CbGpPWpGaD
Indomethacin—PPARG—Metabolism—FH—muscle cancer	3.18e-05	0.00152	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	3.18e-05	0.00152	CbGpPWpGaD
Indomethacin—AKR1C3—Disease—ENO2—muscle cancer	3.15e-05	0.00151	CbGpPWpGaD
Indomethacin—CXCL8—Cellular responses to stress—MDM2—muscle cancer	3.12e-05	0.00149	CbGpPWpGaD
Indomethacin—SLC10A1—Metabolism—ENO2—muscle cancer	3.07e-05	0.00147	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism—FH—muscle cancer	2.93e-05	0.0014	CbGpPWpGaD
Indomethacin—PTGDR2—Signaling Pathways—IGF2—muscle cancer	2.92e-05	0.0014	CbGpPWpGaD
Indomethacin—AKR1C3—Metabolism—MED12—muscle cancer	2.9e-05	0.00138	CbGpPWpGaD
Indomethacin—AKR1C3—Disease—HMGA1—muscle cancer	2.87e-05	0.00137	CbGpPWpGaD
Indomethacin—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	2.84e-05	0.00136	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.83e-05	0.00135	CbGpPWpGaD
Indomethacin—PLA2G2A—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.82e-05	0.00135	CbGpPWpGaD
Indomethacin—CXCL8—Signaling by GPCR—PTCH1—muscle cancer	2.79e-05	0.00134	CbGpPWpGaD
Indomethacin—UGT1A1—Metabolism—FH—muscle cancer	2.74e-05	0.00131	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism—FH—muscle cancer	2.74e-05	0.00131	CbGpPWpGaD
Indomethacin—PTGDR2—Signaling Pathways—FOXO1—muscle cancer	2.69e-05	0.00129	CbGpPWpGaD
Indomethacin—CXCL8—Metabolism of proteins—IGF2—muscle cancer	2.64e-05	0.00126	CbGpPWpGaD
Indomethacin—AKR1C3—Metabolism—ENO2—muscle cancer	2.64e-05	0.00126	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—FH—muscle cancer	2.64e-05	0.00126	CbGpPWpGaD
Indomethacin—ABCC4—Hemostasis—IGF2—muscle cancer	2.63e-05	0.00126	CbGpPWpGaD
Indomethacin—CXCL8—GPCR downstream signaling—CNR1—muscle cancer	2.6e-05	0.00124	CbGpPWpGaD
Indomethacin—AKR1C3—Disease—FOXO4—muscle cancer	2.57e-05	0.00123	CbGpPWpGaD
Indomethacin—ALB—Selenium Micronutrient Network—PTGS2—muscle cancer	2.57e-05	0.00123	CbGpPWpGaD
Indomethacin—PPARA—Metabolism—MED12—muscle cancer	2.51e-05	0.0012	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—FH—muscle cancer	2.51e-05	0.0012	CbGpPWpGaD
Indomethacin—PPARG—Developmental Biology—FOXO1—muscle cancer	2.48e-05	0.00119	CbGpPWpGaD
Indomethacin—PPARA—Circadian rythm related genes—TP53—muscle cancer	2.45e-05	0.00117	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—ANGPT2—muscle cancer	2.45e-05	0.00117	CbGpPWpGaD
Indomethacin—SLC10A1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.4e-05	0.00115	CbGpPWpGaD
Indomethacin—CXCL8—Cellular responses to stress—VEGFA—muscle cancer	2.37e-05	0.00113	CbGpPWpGaD
Indomethacin—CXCL8—Cellular Senescence—TP53—muscle cancer	2.37e-05	0.00113	CbGpPWpGaD
Indomethacin—CXCL8—Signaling by GPCR—CNR1—muscle cancer	2.36e-05	0.00113	CbGpPWpGaD
Indomethacin—PPARG—Gene Expression—MED12—muscle cancer	2.31e-05	0.00111	CbGpPWpGaD
Indomethacin—ALB—Platelet activation, signaling and aggregation—IGF2—muscle cancer	2.31e-05	0.0011	CbGpPWpGaD
Indomethacin—PPARA—Metabolism—ENO2—muscle cancer	2.29e-05	0.00109	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.25e-05	0.00107	CbGpPWpGaD
Indomethacin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	2.23e-05	0.00107	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—FH—muscle cancer	2.23e-05	0.00107	CbGpPWpGaD
Indomethacin—ALB—Platelet degranulation—VEGFA—muscle cancer	2.18e-05	0.00104	CbGpPWpGaD
Indomethacin—ABCC4—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	2.14e-05	0.00102	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—PTCH1—muscle cancer	2.09e-05	0.001	CbGpPWpGaD
Indomethacin—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—muscle cancer	2.08e-05	0.000995	CbGpPWpGaD
Indomethacin—AKR1C3—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.06e-05	0.000987	CbGpPWpGaD
Indomethacin—PTGDR2—Signaling Pathways—KIT—muscle cancer	2.05e-05	0.00098	CbGpPWpGaD
Indomethacin—ABCB1—Allograft Rejection—VEGFA—muscle cancer	1.93e-05	0.000924	CbGpPWpGaD
Indomethacin—ALB—Folate Metabolism—TP53—muscle cancer	1.93e-05	0.00092	CbGpPWpGaD
Indomethacin—UGT2B7—Metabolism—MED12—muscle cancer	1.9e-05	0.00091	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism—MED12—muscle cancer	1.9e-05	0.00091	CbGpPWpGaD
Indomethacin—AKR1C3—Disease—FOXO1—muscle cancer	1.9e-05	0.000907	CbGpPWpGaD
Indomethacin—ALB—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.82e-05	0.000869	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—FOXO4—muscle cancer	1.8e-05	0.00086	CbGpPWpGaD
Indomethacin—PPARG—Metabolism—MED12—muscle cancer	1.8e-05	0.00086	CbGpPWpGaD
Indomethacin—CXCL8—Cellular responses to stress—TP53—muscle cancer	1.79e-05	0.000857	CbGpPWpGaD
Indomethacin—PPARA—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.79e-05	0.000856	CbGpPWpGaD
Indomethacin—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	1.77e-05	0.000847	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—FH—muscle cancer	1.77e-05	0.000847	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—CNR1—muscle cancer	1.77e-05	0.000845	CbGpPWpGaD
Indomethacin—PPARG—Circadian rythm related genes—TP53—muscle cancer	1.76e-05	0.000839	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism—ENO2—muscle cancer	1.73e-05	0.000829	CbGpPWpGaD
Indomethacin—UGT2B7—Metabolism—ENO2—muscle cancer	1.73e-05	0.000829	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism—MED12—muscle cancer	1.66e-05	0.000792	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—PTCH1—muscle cancer	1.65e-05	0.000789	CbGpPWpGaD
Indomethacin—PPARG—Metabolism—ENO2—muscle cancer	1.64e-05	0.000784	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.63e-05	0.00078	CbGpPWpGaD
Indomethacin—ABCC1—Disease—ENO2—muscle cancer	1.62e-05	0.000776	CbGpPWpGaD
Indomethacin—PTGDR2—Signaling Pathways—MDM2—muscle cancer	1.62e-05	0.000772	CbGpPWpGaD
Indomethacin—PPARA—Developmental Biology—VEGFA—muscle cancer	1.58e-05	0.000755	CbGpPWpGaD
Indomethacin—UGT1A1—Metabolism—MED12—muscle cancer	1.55e-05	0.000739	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism—MED12—muscle cancer	1.55e-05	0.000739	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism—ENO2—muscle cancer	1.51e-05	0.000722	CbGpPWpGaD
Indomethacin—PTGS2—Spinal Cord Injury—TP53—muscle cancer	1.5e-05	0.000715	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—MED12—muscle cancer	1.49e-05	0.000713	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.49e-05	0.000711	CbGpPWpGaD
Indomethacin—ABCC1—Disease—HMGA1—muscle cancer	1.48e-05	0.000705	CbGpPWpGaD
Indomethacin—AKR1C3—Disease—KIT—muscle cancer	1.45e-05	0.000691	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—IGF2—muscle cancer	1.44e-05	0.000691	CbGpPWpGaD
Indomethacin—ALB—Metabolism—FH—muscle cancer	1.43e-05	0.000685	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—FOXO4—muscle cancer	1.42e-05	0.000679	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—MED12—muscle cancer	1.42e-05	0.000677	CbGpPWpGaD
Indomethacin—UGT1A1—Metabolism—ENO2—muscle cancer	1.41e-05	0.000674	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism—ENO2—muscle cancer	1.41e-05	0.000674	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—CNR1—muscle cancer	1.39e-05	0.000666	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—ENO2—muscle cancer	1.36e-05	0.00065	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.36e-05	0.000649	CbGpPWpGaD
Indomethacin—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.35e-05	0.000644	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—FOXO1—muscle cancer	1.33e-05	0.000635	CbGpPWpGaD
Indomethacin—ABCC1—Disease—FOXO4—muscle cancer	1.32e-05	0.000633	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—ENO2—muscle cancer	1.29e-05	0.000618	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—FH—muscle cancer	1.29e-05	0.000615	CbGpPWpGaD
Indomethacin—PPARG—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.28e-05	0.000613	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—MED12—muscle cancer	1.26e-05	0.000603	CbGpPWpGaD
Indomethacin—PLA2G2A—Metabolism—PTGS2—muscle cancer	1.26e-05	0.000601	CbGpPWpGaD
Indomethacin—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	1.26e-05	0.000601	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—FH—muscle cancer	1.26e-05	0.0006	CbGpPWpGaD
Indomethacin—PTGDR2—Signaling Pathways—VEGFA—muscle cancer	1.23e-05	0.000586	CbGpPWpGaD
Indomethacin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	1.21e-05	0.000579	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—IGF2—muscle cancer	1.19e-05	0.000569	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.18e-05	0.000565	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—FH—muscle cancer	1.17e-05	0.000561	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—ENO2—muscle cancer	1.15e-05	0.000549	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—IGF2—muscle cancer	1.14e-05	0.000545	CbGpPWpGaD
Indomethacin—AKR1C3—Disease—MDM2—muscle cancer	1.14e-05	0.000545	CbGpPWpGaD
Indomethacin—PPARG—Developmental Biology—VEGFA—muscle cancer	1.13e-05	0.000541	CbGpPWpGaD
Indomethacin—ABCC4—Hemostasis—VEGFA—muscle cancer	1.1e-05	0.000528	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.1e-05	0.000527	CbGpPWpGaD
Indomethacin—AKR1C3—Disease—PTGS2—muscle cancer	1.1e-05	0.000525	CbGpPWpGaD
Indomethacin—PTGS2—Disease—ENO2—muscle cancer	1.09e-05	0.000521	CbGpPWpGaD
Indomethacin—SLC10A1—Metabolism—PTGS2—muscle cancer	1.07e-05	0.000511	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.06e-05	0.000508	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—FOXO1—muscle cancer	1.05e-05	0.000501	CbGpPWpGaD
Indomethacin—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.02e-05	0.000486	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—KIT—muscle cancer	1.01e-05	0.000484	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.01e-05	0.000483	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—MED12—muscle cancer	1e-05	0.000478	CbGpPWpGaD
Indomethacin—PTGS2—Disease—HMGA1—muscle cancer	9.9e-06	0.000473	CbGpPWpGaD
Indomethacin—ABCC1—Disease—FOXO1—muscle cancer	9.77e-06	0.000467	CbGpPWpGaD
Indomethacin—ALB—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	9.69e-06	0.000463	CbGpPWpGaD
Indomethacin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	9.54e-06	0.000456	CbGpPWpGaD
Indomethacin—PTGDR2—Signaling Pathways—TP53—muscle cancer	9.27e-06	0.000443	CbGpPWpGaD
Indomethacin—AKR1C3—Metabolism—PTGS2—muscle cancer	9.2e-06	0.00044	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—ENO2—muscle cancer	9.12e-06	0.000436	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	8.99e-06	0.00043	CbGpPWpGaD
Indomethacin—PTGS2—Disease—FOXO4—muscle cancer	8.88e-06	0.000425	CbGpPWpGaD
Indomethacin—ABCC4—Hemostasis—TP53—muscle cancer	8.34e-06	0.000399	CbGpPWpGaD
Indomethacin—ALB—Metabolism—MED12—muscle cancer	8.1e-06	0.000387	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—KIT—muscle cancer	7.99e-06	0.000382	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—MDM2—muscle cancer	7.98e-06	0.000381	CbGpPWpGaD
Indomethacin—PPARA—Metabolism—PTGS2—muscle cancer	7.97e-06	0.000381	CbGpPWpGaD
Indomethacin—ABCC1—Disease—KIT—muscle cancer	7.45e-06	0.000356	CbGpPWpGaD
Indomethacin—ALB—Metabolism—ENO2—muscle cancer	7.38e-06	0.000353	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—MED12—muscle cancer	7.27e-06	0.000347	CbGpPWpGaD
Indomethacin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	7.21e-06	0.000345	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—MED12—muscle cancer	7.09e-06	0.000339	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—MED12—muscle cancer	6.63e-06	0.000317	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—ENO2—muscle cancer	6.63e-06	0.000317	CbGpPWpGaD
Indomethacin—PTGS2—Disease—FOXO1—muscle cancer	6.56e-06	0.000314	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—ENO2—muscle cancer	6.47e-06	0.000309	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—MDM2—muscle cancer	6.29e-06	0.000301	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—VEGFA—muscle cancer	6.06e-06	0.00029	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism—PTGS2—muscle cancer	6.04e-06	0.000289	CbGpPWpGaD
Indomethacin—UGT2B7—Metabolism—PTGS2—muscle cancer	6.04e-06	0.000289	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—ENO2—muscle cancer	6.04e-06	0.000289	CbGpPWpGaD
Indomethacin—ABCC1—Disease—MDM2—muscle cancer	5.86e-06	0.00028	CbGpPWpGaD
Indomethacin—ALB—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	5.77e-06	0.000276	CbGpPWpGaD
Indomethacin—PPARG—Metabolism—PTGS2—muscle cancer	5.71e-06	0.000273	CbGpPWpGaD
Indomethacin—ABCC1—Disease—PTGS2—muscle cancer	5.65e-06	0.00027	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism—PTGS2—muscle cancer	5.26e-06	0.000252	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	5.18e-06	0.000248	CbGpPWpGaD
Indomethacin—PTGS2—Disease—KIT—muscle cancer	5e-06	0.000239	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—VEGFA—muscle cancer	4.99e-06	0.000239	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism—PTGS2—muscle cancer	4.91e-06	0.000235	CbGpPWpGaD
Indomethacin—UGT1A1—Metabolism—PTGS2—muscle cancer	4.91e-06	0.000235	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—VEGFA—muscle cancer	4.78e-06	0.000228	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—PTGS2—muscle cancer	4.73e-06	0.000226	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	4.73e-06	0.000226	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—TP53—muscle cancer	4.58e-06	0.000219	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—PTGS2—muscle cancer	4.5e-06	0.000215	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—PTGS2—muscle cancer	4e-06	0.000191	CbGpPWpGaD
Indomethacin—PTGS2—Disease—MDM2—muscle cancer	3.94e-06	0.000188	CbGpPWpGaD
Indomethacin—ALB—Hemostasis—TP53—muscle cancer	3.77e-06	0.00018	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—TP53—muscle cancer	3.61e-06	0.000173	CbGpPWpGaD
Indomethacin—ALB—Metabolism—PTGS2—muscle cancer	2.57e-06	0.000123	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—PTGS2—muscle cancer	2.31e-06	0.00011	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—PTGS2—muscle cancer	2.25e-06	0.000108	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—PTGS2—muscle cancer	2.1e-06	0.000101	CbGpPWpGaD
